查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1941692

细胞疗法市场规模、份额、趋势及预测（按细胞类型、治疗方法、治疗领域、最终用户和地区划分），2026-2034年

Cell Therapy Market Size, Share, Trends and Forecast by Cell Type, Therapy Type, Therapeutic Area, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 141 Pages | 商品交期: 2-3个工作天内

价格

2025年全球细胞治疗市场规模为180亿美元。 IMARC集团预测，到2034年，该市场规模将达到610亿美元，2026年至2034年的复合年增长率（CAGR）为14.55%。北美目前占据市场主导地位，预计2025年将占据超过59.8%的市场。随着全球医疗基础设施的完善，干细胞研究的进展也正在加速。意识提升、政府支持的加强以及保险覆盖范围的扩大也是推动市场发展的关键因素。

细胞疗法市场的发展主要得益于再生医学的进步、研发投入的增加以及癌症和自体免疫疾病等慢性病的盛行率上升。干细胞技术和CAR-T疗法的创新正在提高治疗效果，并促进其广泛应用。例如，2024年6月，南加州大学的研究人员开发了一种利用机器学习的非侵入性成像方法，用于研究造血干细胞。这项突破性技术能够即时追踪干细胞的行为和代谢，加深我们对干细胞复製和分化的理解。这可能对骨髓移植和再生医学等治疗方法产生深远影响。监管部门的核准和不断增加的临床试验进一步推动了市场成长。对个人化医疗日益增长的需求推动了人们对细胞疗法的兴趣，而不断完善的医疗基础设施和报销政策则提高了其可及性。此外，生技公司和研究机构之间的合作正在加速突破，使细胞疗法成为满足全球医疗保健未满足需求的理想解决方案。

美国细胞疗法市场的发展动力源于对慢性疾病（尤其是癌症和自体免疫疾病）创新治疗方法日益增长的需求。根据美国国家癌症研究所发布的数据，预计到2024年，美国将新增约2,001,140例癌症病例，并有611,720人死于癌症。其中，乳癌、摄护腺癌、肺癌和大肠癌是主要癌症类型，分别占男性癌症诊断总数的48%和女性癌症诊断总数的51%。癌症发生率的上升正在推动美国各地对细胞疗法的需求。 CAR-T细胞疗法和干细胞研究的进展是市场扩张的关键驱动因素。政府的大力资助、不断增加的临床试验以及快速的监管核准正在强化开发平臺。个人化医疗的普及，以及医疗基础设施和报销机制的完善，正在加速细胞疗法的应用。此外，生物技术公司、学术机构和製药公司之间的合作也在促进创新。

细胞疗法市场趋势：

包括癌症和心臟病在内的各种疾病的发生率增加

包括癌症和心臟病在内的多种疾病日益普遍，对市场产生了积极影响。由于人口老化、生活方式改变和环境因素等原因，这些疾病的全球负担正在稳步加重。世界卫生组织（WHO）的数据显示，2020年全球新增癌症病例约1,930万例，凸显了创新治疗方法的迫切需求。细胞疗法利用特化细胞的再生和修復能力，具有治疗甚至治癒多种疾病的潜力。在癌症治疗方面，CAR-T细胞疗法等以细胞为基础的免疫疗法在标靶和清除癌细胞方面取得了显着成效。在心臟病治疗方面，基于干细胞的治疗方法旨在修復受损的心臟组织并改善心臟功能。对这些广泛流行且危及生命的疾病进行有效治疗方法的迫切需求，正在推动细胞疗法领域的广泛研究、开发和投资。

增加对细胞疗法的临床研究

细胞疗法临床研究数量的不断增长正在推动细胞疗法市场的发展。根据ClinicalTrials.gov网站统计，截至2024年，全球已有超过2,000项临床试验正在进行中。临床试验在检验这些创新治疗方法的安全性和有效性方面发挥着至关重要的作用。随着临床研究的拓展，包括癌症、自体免疫疾病和退化性疾病在内的多种疾病对创新治疗方法的需求日益增长。生技公司、製药公司和学术机构正积极进行这些研究，旨在实现细胞疗法的商业化。这些研究获得的大量数据不仅展现了细胞疗法的治疗潜力，还有助于改进治疗通讯协定并确定最佳患者群体。此外，美国食品药物管理局（FDA）等监管机构也积极支持并加速细胞疗法的核准流程，进一步促进了临床试验的启动。因此，越来越多的临床试验正在推动细胞疗法的发展，激发创新思维，同时扩大有需要的患者获得治疗的机会。这项因素凸显了临床研究在推动市场发展的重要角色。

全球不断扩张的医疗保健产业

全球医疗保健产业的蓬勃发展为市场带来了光明的前景。随着人口增长和老化，慢性疾病负担日益加重，对先进疗法的需求也显着增长。医疗保健产业的扩张也包括细胞疗法等最先进治疗的研发。全球医疗保健系统日益认识到细胞疗法在治疗包括自体免疫、神经系统疾病、心血管疾病和癌症在内的多种疾病方面的潜力。这种日益增长的认知促使再生医学和细胞疗法领域的投资、研究和临床试验不断增加。此外，新兴国家医疗基础设施的建设也扩大了包括细胞疗法在内的前沿疗法的可近性。目前，全球有超过1200项临床试验正在评估细胞疗法，凸显了研究工作的持续深入。全球医疗保健服务的扩张扩大了细胞疗法的潜在患者群体，从而推动了市场成长。

目录

第一章：序言

第二章：调查范围与调查方法

  • 调查目标
  • 相关利益者
  • 数据来源
    • 主要讯息
    • 次要讯息
  • 市场估值
    • 自下而上的方法
    • 自上而下的方法
  • 调查方法

第三章执行摘要

第四章 引言

第五章 全球细胞治疗市场

  • 市场概览
  • 市场表现
  • 新冠疫情的影响
  • 市场预测

第六章 依细胞类型分類的市场细分

  • 干细胞
    • 主要部分
      • 骨髓
      • 血
      • 脐带来源
      • 脂肪来源干细胞
      • 其他的
  • 非干细胞

第七章 按治疗方法分類的市场区隔

  • 自体移植
  • 同种异体移植

第八章 按治疗领域分類的市场区隔

  • 恶性肿瘤
  • 肌肉骨骼疾病
  • 自体免疫疾病
  • 皮肤科
  • 其他的

第九章 依最终用户分類的市场细分

  • 医院和诊所
  • 学术研究机构

第十章 按地区分類的市场细分

  • 北美洲
    • 我们
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第十一章 SWOT 分析

第十二章 价值链分析

第十三章 波特五力分析

第十四章：定价分析

第十五章 竞争格局

  • 市场结构
  • 主要企业
  • 主要企业简介
    • Allogene Therapeutics
    • AlloSource
    • Bristol-Myers Squibb Company
    • Corestemchemon Inc
    • Gilead Sciences, Inc.
    • Holostem Srl
    • IOVANCE Biotherapeutics, Inc.
    • JCR Pharmaceuticals Co., Ltd
    • Legend Biotech
    • Mesoblast Ltd.
    • Sangamo Therapeutics
    • Tegoscience
    • Vericel Corporation
Product Code: SR112026A6231

The global cell therapy market size was valued at USD 18.0 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 61.0 Billion by 2034, exhibiting a CAGR of 14.55% during 2026-2034. North America currently dominates the market, holding a significant market share of over 59.8% in 2025. The advancements in stem cell research are on the rise along with the development of healthcare infrastructure worldwide. Increasing patient awareness, heightened government support and broader insurance coverage are also key factors driving the market forward.

The cell therapy market is driven by advancements in regenerative medicine, increasing investment in research and development and rising prevalence of chronic diseases like cancer and autoimmune disorders. Innovations in stem cell technology and CAR-T therapies are enhancing treatment effectiveness, and driving adoption. For instance, in June 2024, researchers at USC developed a non-invasive imaging method using machine learning to study hematopoietic stem cells. This breakthrough allows for real-time tracking of stem cell behavior and metabolism improving understanding of their replication and differentiation with potential implications for therapies like bone marrow transplants and regenerative medicine. Regulatory approvals and growing clinical trials further boost market growth. The demand for personalized medicine is fostering interest in cell based therapies while expanding healthcare infrastructure and reimbursement policies to support accessibility. Additionally, collaborations between biotech companies and research institutions are accelerating breakthroughs making cell therapies a promising solution for unmet medical needs in global healthcare.

The United States cell therapy market is fueled by growing demand for innovative treatments for chronic diseases, particularly cancer and autoimmune disorders. According to data published by the National Cancer Institute, in 2024 the United States will witness approximately 2,001,140 new cancer cases with 611,720 deaths. Common cancers include breast, prostate, lung and colorectal comprising 48% of diagnoses in men and 51% in women. Rising incidence of cancer is driving the demand for cell therapy across the country. Advancements in CAR-T cell therapy and stem cell research are key contributors to market expansion. Robust government funding, increasing clinical trials and faster regulatory approvals enhance the development pipeline. The adoption of personalized medicine is accelerating the use of cell therapies supported by improved healthcare infrastructure and reimbursement frameworks. Additionally, collaborations between biotech firms, academic institutions and pharmaceutical companies are fostering innovation.

Cell Therapy Market Trends:

Increasing Prevalence of Various Diseases, Such as Cancer and Cardiac Abnormalities

The increasing prevalence of various diseases particularly cancer and cardiac abnormalities is favorably impacting the market. The global burden of these diseases has steadily risen due to factors like aging populations, lifestyle changes and environmental influences. According to the World Health Organization (WHO), cancer accounted for approximately 19.3 million new cases globally in 2020, highlighting the urgent need for innovative therapies. By using the regenerative and reparative capabilities of specialized cells, cell therapy has enormous potential for treating and even curing various diseases. For cancer, cell-based immunotherapies such as CAR-T cell therapy have shown remarkable success in targeting and eliminating cancer cells. In the case of cardiac abnormalities stem cell-based therapies aim to repair damaged heart tissue and improve cardiac function. The urgent need for effective treatments for these widespread and life-threatening diseases propels extensive research, development, and investment in cell therapy approaches.

Rising Number of Clinical Studies for Cell-based Therapies

The rising number of clinical studies for cell based therapies is fueling the cell therapy market growth with over 2,000 active clinical trials globally as of 2024, according to ClinicalTrials.gov. Clinical trials play a fundamental role in validating the safety and efficacy of these innovative treatments. The need for innovative treatments to treat a range of illnesses, including cancer, autoimmune diseases, and degenerative disorders, is increasing as clinical research expands. These studies are being actively carried out by biotechnology firms, pharmaceutical corporations, and academic institutions to commercialize cell-based medicines. The wealth of data generated from these studies demonstrates the therapeutic potential of cell therapies but also aids in refining treatment protocols and identifying the most suitable patient populations. Moreover, regulatory agencies like the FDA in the United States actively support and expedite the approval process for cell-based therapies further incentivizing the initiation of clinical trials. Consequently, a rising number of clinical trials propels the development of cell therapies, encouraging creativity and boosting their availability to patients in need. This factor underscores the significant role clinical research plays in propelling the market.

Expanding Healthcare Industry Worldwide

The growing healthcare sector across the globe is creating a positive market outlook. As populations grow, age and face an increasing burden of chronic diseases the demand for advanced medical treatments rises significantly. The healthcare sector's expansion includes the development of cutting-edge therapies like cell-based treatments. Global healthcare systems are realizing that cell therapy can be used to treat a variety of illnesses, including autoimmune diseases, neurological disorders, cardiovascular diseases, and cancer. This recognition translates into increased investment, research and clinical trials in regenerative medicine and cell therapy. Furthermore, access to cutting-edge medical treatments, such as cell therapies, is increasing in emerging nations as healthcare infrastructure advances. Additionally, over 1,200 clinical trials globally are currently evaluating cell therapies highlighting growing research efforts. This global expansion of healthcare services broadens the potential patient pool for cell-based treatments driving market growth.

Cell Therapy Industry Segmentation:

Analysis by Cell Type:

  • Stem Cell
    • Bone Marrow
    • Blood
    • Umbilical Cord-Derived
    • Adipose-Derived Stem Cell
    • Others
  • Non-stem Cell

Stem cells with their remarkable regenerative potential and ability to differentiate into various cell types have garnered significant attention in the medical field. These versatile cells are instrumental in treating a wide spectrum of diseases including degenerative disorders, neurological conditions and hematological malignancies. The increasing prevalence of age-related diseases and chronic conditions has intensified the demand for effective stem cell-based treatments. Moreover, ongoing research and clinical trials continue to unveil new therapeutic possibilities for stem cells further fueling market growth. Pharmaceutical and biotechnology firms heavily invest in stem cell research focusing on developing innovative therapies. Furthermore, regulatory agencies are recognizing the importance of stem cell therapies, streamlining approval processes and safety standards. This facilitates the commercialization of stem cell-based treatments making them more accessible to patients worldwide. The stem cell segment is a powerful driver of growth in the cell therapy market promising revolutionary solutions for numerous medical challenges.

Analysis by Therapy Type:

  • Autologous
  • Allogeneic

Autologous leads the market with around 91.6% of market share in 2025. Autologous therapies involve the extraction, manipulation and reinfusion of a patient's cells minimizing the risk of rejection and adverse reactions. This personalized approach has gained prominence in treating various conditions including cancer, autoimmune diseases and degenerative disorders. The increasing demand for therapies with higher safety profiles and reduced immune complications has fueled the adoption of autologous cell therapies. These treatments harness the regenerative potential of a patient's cells addressing unmet medical needs while minimizing the risks associated with allogeneic treatments where cells are sourced from donors.

Furthermore, advancements in cell processing techniques such as CAR-T cell therapies for cancer treatment showcase the remarkable potential of autologous therapies. Regulatory agencies are also streamlining approval pathways for these personalized treatments expediting their availability to a wider patient population. As a result the autologous therapy segment is a pivotal driver of growth in the cell therapy market offering innovative and patient-centric solutions for various medical conditions.

Analysis by Therapeutic Area:

  • Malignancies
  • Musculoskeletal Disorders
  • Autoimmune Disorders
  • Dermatology
  • Others

Malignancies including various types of cancer present one of the most challenging healthcare concerns globally. Cell therapies such as CAR-T have emerged as groundbreaking treatments for these conditions. The growing incidence of cancer and the increasing demand for more effective and targeted therapies have propelled the development and adoption of cell based treatments. These therapies harness the patient's immune system or engineered cells to target and eliminate cancer cells. Their remarkable success in clinical trials and real-world applications underscores their potential to transform cancer treatment.

Moreover, regulatory agencies are expediting approvals for cell therapies in oncology streamlining their path to market. As a result, the malignancies focused segment serves as a critical driver of growth in the cell therapy market offering renewed hope to cancer patients and contributing to the evolution of cancer care. The cell therapy market forecast anticipates sustained growth driven by the demand for innovative and targeted treatments like CAR-T therapy particularly within the oncology segment.

Analysis by End User:

  • Hospitals and Clinics
  • Academic and Research Institutes

Hospitals and clinics serve as primary end users of cell therapy due to their advanced infrastructure and skilled medical staff. These facilities support a range of therapies including regenerative treatments for chronic diseases, cancer and autoimmune disorders. The growing prevalence of conditions requiring cell-based solutions combined with increasing patient awareness drives the adoption of cell therapy in these settings. Moreover, advancements in stem cell banking and enhanced government funding for hospital based research further strengthen their role in the cell therapy market.

Academic and research institutes are key end users in the cell therapy market driving innovation and development. These centers study cellular mechanisms, test new therapies, and conduct clinical trials. Their access to specialized labs and collaborative networks enables the development of cutting-edge treatments. Government and private funding initiatives for R&D alongside partnerships with biotech firms amplify their contributions to the market. These institutions are vital for translating scientific breakthroughs into clinical applications.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, North America accounted for the largest market share of over 59.8%. North America boasts a robust and highly developed healthcare infrastructure including advanced research institutions, hospitals and clinical centers. These institutions actively engage in cell therapy research and clinical trials accelerating the development and adoption of innovative cell-based treatments. The substantial investments in the biotechnology and pharmaceutical sectors facilitate the advancement of cell therapies. Pharmaceutical companies and biotech firms in the region actively contribute to cell therapy research and development resulting in a steady stream of new therapies.

The regulatory agencies in North America such as the FDA in the United States play a crucial role in streamlining the approval process for cell therapies ensuring they meet rigorous safety and efficacy standards. This regulatory support expedites the commercialization of these treatments. Moreover, the increasing prevalence of chronic diseases including cancer fuels the demand for effective and advanced therapies making cell therapies an attractive option for patients and healthcare providers.

Key Regional Takeaways:

United States Cell Therapy Market Analysis

In 2025, the United States accounted for a share of 92.80% of the North America market. With immense investment in R&D and clinical advancements, the U.S. cell therapy market is booming. According to the Alliance for Regenerative Medicine, global cell and gene therapy investment has hit USD 23.1 Billion in 2023; most of which have come from the United States. The high prevalence of chronic diseases such as cancer and diabetes fuels the adoption of therapies like CAR-T and stem cell treatment, together with favorable FDA policies. Focus is put on innovation, as from 2023 when over 2,000 clinical trials for cell therapy had already been running. Leading players in this space include companies from Novartis and Gilead Sciences, with new pipeline growth from collaboration with academia and biotech companies. In developing initiatives, the government-initiated schemes, such as the 21st Century Cures Act, are complemented by collaboration with payers over the cost issues. The US is also using export opportunities to build on its leadership position worldwide in cell therapy.

Europe Cell Therapy Market Analysis

Europe has a growing cell therapy market, thanks to strong R&D support, advances in regulations, and increasing healthcare budgets. In 2023, more than 150 ATMPs, including cell therapies, were in some form of clinical trials according to EMA. Germany is on top with considerable funding that was allocated to regenerative medicine projects last 2022 to the tune of USD 200 Million. The growth in the region is driven by CAR-T cell therapies for oncology and mesenchymal stem cells for degenerative diseases. The Association of the British Pharmaceutical Industry stated that there are over 90 cell therapy companies in the UK, which contribute highly to exports and employment. The EU regulations focus on safety and innovation, which encourages the use of innovative technologies. The collaboration between universities and biotech firms is enhancing the competitiveness of the market in the global arena. Such is the case for France and the Netherlands.

Asia Pacific Cell Therapy Market Analysis

The Asia Pacific cell therapy market is growing rapidly owing to the increasing investments and regional advancements in health care. India's Biotechnology Industry Research Assistance Council released USD 500 Million in 2023 for translational research. Japan's Act on the Safety of Regenerative Medicine and streamlined regulatory routes have accelerated market growth, with more than 30 cell therapies approved by 2023. Several countries, such as South Korea and Australia, are leading early clinical trials for new therapies via state-sponsored work. The partnerships between regional biotech companies and global leaders, like the CAR-T collaboration by Fosun Kite Biotechnology, are drivers of technology transfer. Also, low manufacturing cost in the region will give the Asia Pacific a critical place in the global cell therapy landscape.

Latin America Cell Therapy Market Analysis

Government support and increased local manufacturing drive Latin America's momentum in cell therapy. According to ProMedica International, biopharmaceuticals are allocated to the tune of USD 1.5 Billion, as announced in 2022 by Brazil. Clinical trials in Mexico will be focused on the increasing number of infrastructures; 50 or more trials were ongoing at the end of 2023. Other conditions that require regenerative medicine are type 2 diabetes and cardiovascular diseases. Colombia is also investing in stem cell research. Academic collaborations and government funding support the effort. A leader in the industry is Cellavita in Brazil, which is increasing production capacity to meet both the local and export markets. In addition, innovations in manufacturing cost-effective cell therapy help improve healthcare access in this region. Partnerships with global biotechnology companies will further strengthen Latin America's position in the global market while promoting regional R&D capabilities.

Middle East and Africa Cell Therapy Market Analysis

Middle East and Africa the cell therapy market is steadily growing on account of healthcare modernization and research investment. For instance, in 2023, the International Trade Administration reported that Saudi Arabia has allocated a budget to healthcare amounting to about USD 50.4 Billion to support improvements in the area of regenerative medicine. South Africa is regional frontrunner for the stem cell-based therapy initiatives developed and supported by the country's Department of Science and Innovation. The UAE is developing cell therapy research medical hubs through joint work with global institutions, the country's focus centers around sickle cell disease and diabetes treatments, issues within the region. By forming partnerships with international entities and acquiring government funding grants, the manufacturing capabilities to ensure these products are affordable, available, and accessible by increasing healthcare infrastructure, Africa and the Middle East are bound to be one of the rising contributors in the Cell Therapy market.

Competitive Landscape:

Major companies are bolstering the market with an array of offerings and methods. These pioneers in the field place a high priority on thorough research and development, constantly expanding the possibilities of cell therapies through the investigation of new cell types, delivery systems, and uses. They conduct rigorous clinical trials, substantiating the safety and efficacy of their therapies and obtaining regulatory approvals that enhance market credibility. They can take advantage of the combined expertise and resources of research institutions, biotech companies, and healthcare organizations through strategic alliances and collaborations. Leading businesses frequently broaden their market reach internationally, enabling a larger patient pool to access cell therapies. Maintaining strict compliance with regulatory standards ensures that their therapies meet stringent safety and quality requirements, instilling confidence among healthcare professionals and patients. Additionally, their crucial role in developing cell therapies and promoting market expansion is further reinforced by patient access improvement programs, educational campaigns, and strategic acquisitions.

The report has provided a comprehensive analysis of the competitive landscape in the cell therapy market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Allogene Therapeutics
  • AlloSource
  • Bristol-Myers Squibb Company
  • Corestemchemon Inc
  • Gilead Sciences, Inc.
  • Holostem S.r.l
  • IOVANCE Biotherapeutics, Inc.
  • JCR Pharmaceuticals Co., Ltd
  • Legend Biotech
  • Mesoblast Ltd.
  • Sangamo Therapeutics
  • Tegoscience
  • Vericel Corporation

Key Questions Answered in This Report

  • 1.What is cell therapy?
  • 2.How big is the cell therapy market?
  • 3.What is the expected growth rate of the global cell therapy market during 2026-2034?
  • 4.What are the key factors driving the global cell therapy market?
  • 5.What is the leading segment of the global cell therapy market based on cell type?
  • 6.What is the leading segment of the global cell therapy market based on therapy type?
  • 7.What is the leading segment of the global cell therapy market based on therapeutic area?
  • 8.What are the key regions in the global cell therapy market?
  • 9.Who are the key players/companies in the global cell therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Cell Therapy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Cell Type

  • 6.1 Stem Cell
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Bone Marrow
      • 6.1.2.2 Blood
      • 6.1.2.3 Umbilical Cord-Derived
      • 6.1.2.4 Adipose-Derived Stem Cell
      • 6.1.2.5 Others
    • 6.1.3 Market Forecast
  • 6.2 Non-stem Cell
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapy Type

  • 7.1 Autologous
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Allogeneic
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Therapeutic Area

  • 8.1 Malignancies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Musculoskeletal Disorders
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Autoimmune Disorders
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Dermatology
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Academic and Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Allogene Therapeutics
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 AlloSource
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Bristol-Myers Squibb Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Corestemchemon Inc
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Gilead Sciences, Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Holostem S.r.l
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 IOVANCE Biotherapeutics, Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 JCR Pharmaceuticals Co., Ltd
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Legend Biotech
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Mesoblast Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
    • 15.3.11 Sangamo Therapeutics
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Tegoscience
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Vericel Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Cell Therapy Market: Major Drivers and Challenges
  • Figure 2: Global: Cell Therapy Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Cell Therapy Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Cell Therapy Market: Breakup by Cell Type (in %), 2025
  • Figure 5: Global: Cell Therapy Market: Breakup by Therapy Type (in %), 2025
  • Figure 6: Global: Cell Therapy Market: Breakup by Therapeutic Area (in %), 2025
  • Figure 7: Global: Cell Therapy Market: Breakup by End User (in %), 2025
  • Figure 8: Global: Cell Therapy Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Cell Therapy (Stem Cell) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Cell Therapy (Stem Cell) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Cell Therapy (Non-stem Cell) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Cell Therapy (Non-stem Cell) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Cell Therapy (Autologous) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Cell Therapy (Autologous) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Cell Therapy (Allogeneic) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Cell Therapy (Allogeneic) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Cell Therapy (Malignancies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Cell Therapy (Malignancies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Cell Therapy (Musculoskeletal Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Cell Therapy (Musculoskeletal Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Cell Therapy (Autoimmune Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Cell Therapy (Autoimmune Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Cell Therapy (Dermatology) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Cell Therapy (Dermatology) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Cell Therapy (Other Therapeutic Areas) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Cell Therapy (Other Therapeutic Areas) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Cell Therapy (Hospitals and Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Cell Therapy (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Cell Therapy (Academic and Research Institutes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Cell Therapy (Academic and Research Institutes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: North America: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: North America: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: United States: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: United States: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Canada: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Canada: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Asia-Pacific: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Asia-Pacific: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: China: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: China: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Japan: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Japan: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: India: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: India: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: South Korea: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: South Korea: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Australia: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Australia: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Indonesia: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Indonesia: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Others: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Others: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Europe: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Europe: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Germany: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Germany: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: France: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: France: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: United Kingdom: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: United Kingdom: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Italy: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Italy: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Spain: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Spain: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Russia: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Russia: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Others: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Others: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Latin America: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Latin America: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Brazil: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Brazil: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Mexico: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Mexico: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Middle East and Africa: Cell Therapy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Middle East and Africa: Cell Therapy Market: Breakup by Country (in %), 2025
  • Figure 79: Middle East and Africa: Cell Therapy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Global: Cell Therapy Industry: SWOT Analysis
  • Figure 81: Global: Cell Therapy Industry: Value Chain Analysis
  • Figure 82: Global: Cell Therapy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Cell Therapy Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Cell Therapy Market Forecast: Breakup by Cell Type (in Million USD), 2026-2034
  • Table 3: Global: Cell Therapy Market Forecast: Breakup by Therapy Type (in Million USD), 2026-2034
  • Table 4: Global: Cell Therapy Market Forecast: Breakup by Therapeutic Area (in Million USD), 2026-2034
  • Table 5: Global: Cell Therapy Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 6: Global: Cell Therapy Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Cell Therapy Market: Competitive Structure
  • Table 8: Global: Cell Therapy Market: Key Players